Skip to content

Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)

Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030116
Enrollment
Unknown
Registered
2020-02-23
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Two groups:Different stem cell doses

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients are eligible for admission if they meet all of the following criteria within 5-7 days of their first ICU admission. 1) Aged 18-75 years; 2) The patient meets the ARDS diagnostic standard (Berlin standard) and needs intubation ventilator-assisted or ECMO-assisted treatment; 3) The primary disease caused by 2019-nCoV virus infection; 4) Imaging data suggest bilateral lung lesions; 5) Voluntarily participate in clinical research; fully understand, know, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) ARDS caused by other viral infections; 2) ARDS caused by other non-viral infections (such as trauma); 3) WHO grade III or IV pulmonary hypertension; 4) Patients with malignant tumors of the lungs and other systems; 5) Positive blood pregnancy test in lactating women or screening women; 6) Idiopathic IgA deficiency; 7) Cardio-cerebrovascular events in the near future (3 months); 8) patients with lung transplantation; 9) HIV positive patients; 10) Tester excluding from the investigator's judgment a history or current evidence of any disease, treatment, or laboratory abnormality that may confuse the results of the study, interfere with the participant's participation in the study process, or are not in the best interest of the participant to participate in the study.

Design outcomes

Primary

MeasureTime frame
Time to leave ventilator on day 28 after receiving MSCs infusion;

Countries

China

Contacts

Public ContactZhang Wei

The First Affiliated Hospital of Nanchang University

zhangweiliuxin@163.com+86 13707089183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026